抗结核药物靶点的结构研究进展

doi:10.3969/j.issn.0253-9608.2021.05.003

摘要/Abstract

摘要： 结核病(tuberculosis)是一种严重威胁人类生命健康的传染性疾病，主要由结核分枝杆菌( Mycobacterium tuberculosis )感染引起。当前结核病的耐药性问题突出，新药的研发刻不容缓。研究抗结核药物靶点的结构将助力药物的开发工作。文章总结了在结核杆菌细胞壁合成和能量代谢这两个重要生理过程中关键药物靶点的最新结构研究进展，分析了这些膜蛋白及其复合物的结构与功能的关系和已知药物分子作用于靶点的精确作用方式，以及对于抗结核新药设计的重要价值。

关键词: 结核病, 药物靶点, 结构生物学, 细胞壁, 糖基转移酶, 呼吸链

Abstract: Tuberculosis, mainly caused by the pathogenic bacteria Mycobacterium tuberculosis , is an infectious disease that seriously threats human life and health. The even worse situation currently is the drug resistance problem. Thus, new anti-tuberculosis drugs are urgently needed. Studies on the structures of anti-tuberculosis drug targets will assist in drug development. This paper summarizes
the latest research progress on structures of the crucial drug targets involved in the two important physiology processes of cell wall biosynthesis and energy metabolism in Mycobacterium tuberculosis , and also analyzes the structure-function relation of these
membrane proteins and their complexes as well as the precise mode of actions of the known drug molecules on these targets, and the important value for the design of new anti-tuberculosis drugs.

陈晓博, 李俊 . 抗结核药物靶点的结构研究进展[J]. 自然杂志, 2021, 43(5): 335-342.

CHEN Xiaobo , LI Jun. Progress on structures of anti-tuberculosis drug targets[J]. Chinese Journal of Nature, 2021, 43(5): 335-342.

参考文献

[1]　World Health Organization. Global tuberculosis report 2020 [R/OL]. Geneva, Switzerland: WHO, 2020. https://www.who.int/
publications/i/item/9789240013131.
[2]　RIVERS E C, MANCERA R L. New anti-tuberculosis drugs with novel mechanisms of action [J]. Curr Med Chem, 2008, 15(19):
1956-1967.
[3]　FRIEDEN T R, STERLING T, PABLOS-MENDEZ A, et al. The emergence of drug-resistant tuberculosis in New York City [J]. N
Engl J Med, 1993, 328(8): 521-526.
[4]　ALEXANDER P E, DE P. The emergence of extensively drug-resistant tuberculosis (TB): TB/HIV coinfection, multidrug-esistant
TB and the resulting public health threat from extensively drug-resistant TB, globally and in Canada [J]. Can J Infect Dis Med Microbiol, 2007, 18(5): 289-291.
[5]　VELAYATI A A, MASJEDI M R, FARNIA P, et al. Emergence of new forms of totally drug-resistant tuberculosis bacilli: super
extensively drug-resistant tuberculosis or totally drug-resistant strains in Iran [J]. Chest, 2009, 136(2): 420-425.
[6]　WRIGHT C C, HSU F F, ARNETT E, et al. The Mycobacterium tuberculosis MmpL11 cell wall lipid transporter is important
for biofilm formation, intracellular growth, and nonreplicating persistence [J]. Infect Immun, 2017, 85(8). DOI: 10.1128/
IAI.00131-17.
[7]　ABRAHAMS K A, BESRA G S. Mycobacterial cell wall biosynthesis: a multifaceted antibiotic target [J]. Parasitology, 2018, 145(2): 116-133.
[8]　BROWN L, WOLF J M, PRADOS-ROSALES R, et al. Through the wall: extracellular vesicles in Gram-positive bacteria, mycobacteria and fungi [J]. Nat Rev Microbiol, 2015, 13(10): 620-630.
[9]　JANKUTE M, COX J A G, HARRISON J, et al. Assembly of the mycobacterial cell wall [J]. Annu Rev Microbiol, 2015, 69: 405-
423.
[10] BHAT Z S, RATHER M A, MAQBOOL M, et al. Cell wall: A versatile fountain of drug targets in Mycobacterium tuberculosi s [J].
Biomed Pharmacother, 2017, 95: 1520-1534.
[11] GRZEGORZEWICZ A E, PHAM H, GUNDI V A K B, et al. Inhibition of mycolic acid transport across the Mycobacterium
tuberculosis plasma membrane [J]. Nat Chem Biol, 2012, 8(4): 334-341.
[12] DOMENECH P, REED M B, BARRY C E. Contribution of the Mycobacterium tuberculosis MmpL protein family to virulence and
drug resistance [J]. Infect Immun, 2005, 73(6): 3492-3501.
[13] VILJOEN A, DUBOIS V, GIRARD-MISGUICH F, et al. The diverse family of MmpL transporters in mycobacteria: from regulation to antimicrobial developments [J]. Mol Microbiol, 2017, 104(6): 889-904.
[14] SACKSTEDER K A, PROTOPOPOVA M, BARRY C, et al. Discovery and development of SQ109: a new antitubercular drug
with a novel mechanism of action [J]. Future Microbiol, 2012, 7(7): 823-837.
[15] ZHANG B, LI J, YANG X, et al. Crystal structures of membrane transporter MmpL3, an anti-TB drug target [J]. Cell, 2019, 176(3): 636-648. e13.
[16] TSUKAZAKI T, MORI H, ECHIZEN Y, et al. Structure and function of a membrane component SecDF that enhances protein
export [J]. Nature, 2011, 474(7350): 235-238.
[17] MURAKAMI S, NAKASHIMA R, YAMASHITA E, et al. Crystal structures of a multidrug transporter reveal a functionally rotating
mechanism [J]. Nature, 2006, 443(7108): 173-179.
[18] EICHER T, SEEGER M A, ANSELMI C, et al. Coupling of remote alternating-access transport mechanisms for protons and substrates in the multidrug efflux pump AcrB [J]. Elife, 2014, 3: e03145. DOI: 10.7554/eLife.03145
[19] RINALDI-CARMONA M, BARTH F, HEAULME M, et al. SR141716A, a potent and selective antagonist of the brain cannabinoid receptor [J]. FEBS Lett, 1994, 350(2/3): 240-244.
[20] ESCUYER V E, LETY M-A, TORRELLES J B, et al. The role of the embA and embB gene products in the biosynthesis of the
terminal hexaarabinofuranosyl motif of Mycobacterium smegmatis arabinogalactan [J]. J Biol Chem, 2001, 276(52): 48854-48862.
[21] ZHANG N, TORRELLES J B, MCNEIL M R, et al. The Emb proteins of mycobacteria direct arabinosylation of lipoarabinomannan and arabinogalactan via an N-terminal recognition region and a C-terminal synthetic region [J]. Mol Microbiol, 2003, 50(1): 69-76.
[22] GOUDE R, AMIN A G, CHATTERJEE D, et al. The critical role of embC in Mycobacterium tuberculosis [J]. J Bacteriol, 2008,
190(12): 4335-4341.
[23] SAFI H, SAYERS B, HAZBON M H, et al. Transfer of embB codon 306 mutations into clinical Mycobacterium tuberculosis strains alters susceptibility to ethambutol, isoniazid, and rifampin [J]. Antimicrob Agents Chemother, 2008, 52(6): 2027-2034.
[24] SUN Q, XIAO T-Y, LIU H-C, et al. Mutations within embCAB are associated with variable level of ethambutol resistance in
Mycobacterium tuberculosis isolates from China [J]. Antimicrob Agents Chemother, 2018, 62(1): e01279-17.
[25] ZHAO L, SUN Q, LIU H, et al. Analysis of embCAB mutations associated with ethambutol resistance in multidrug-resistant
Mycobacterium tuberculosis isolates from China [J]. Antimicrob Agents Chemother, 2015, 59(4): 2045-2050.
[26] BROSSIER F, SOUGAKOFF W, BERNARD C, et al. Molecularanalysis of the embCAB locus and e mbR gene involved in
ethambutol resistance in clinical isolates of Mycobacterium tuberculosis in France [J]. Antimicrob Agents Chemother, 2015,
59(8): 4800-4808.
[27] ZHANG L, ZHAO Y, GAO Y, et al. Structures of cell wall arabinosyltransferases with the anti-tuberculosis drug ethambutol
[J]. Science, 2020, 368(6496): 1211-1219.
[28] BORASTON A B, BOLAM D N, GILBERT H J, et al. Carbohydrate-binding modules: fine-tuning polysaccharide recognition [J]. Biochem J, 2004, 382(Pt 3): 769-781.
[29] PLINKE C, COX H S, ZARKUA N, et al. embCAB sequence variation among ethambutol-resistant Mycobacterium tuberculosis
isolates without embB 306 mutation [J]. J Antimicrob Chemother, 2010, 65(7): 1359-1367.
[30] COLE S T, BROSCH R, PARKHILL J, et al. Deciphering the biology of Mycobacterium tuberculosis from the complete genome
sequence [J]. Nature, 1998, 393(6685): 537-544.
[31] MEGEHEE J A, HOSLER J P, LUNDRIGAN M D. Evidence for a cytochrome bcc-aa3 interaction in the respiratory chain of
Mycobacterium smegmatis [J]. Microbiology (Reading), 2006, 152(Pt 3): 823-829.
[32] KAO W-C, KLEINSCHROTH T, NITSCHKE W, et al. The obligate respiratory supercomplex from Actinobacteria [J]. Biochim Biophys Acta, 2016, 1857(10): 1705-1714.
[33] PETHE K, BIFANI P, JANG J, et al. Discovery of Q203, a potent clinical candidate for the treatment of tuberculosis [J]. Nat Med, 2013, 19(9): 1157-1160.
[34] GONG H, LI J, XU A, et al. An electron transfer path connects subunits of a mycobacterial respiratory supercomplex [J]. Science, 2018, 362(6418): eaat8923. DOI: 10.1126/science.aat8923.